3 Rumors Pushing Around Stocks Today
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Jefferies sees up to 90% chance Horizon Therapeutics (HZNP) gets acquired, with $125 base case
December 1, 2022 11:06 AM ESTJefferies analyst Akash Tewari was the latest Wall Street analyst to weigh in on the takeover prospects of Horizon Therapeutics (NASDAQ: HZNP) after the company announced Tuesday that it is in preliminary talks with three large pharmaceutical companies about a potential buyout.
Tewari is positive on the prospects of a deal and sees one happening in the $25-$30 billion range, which he also said does not bake in Tepezza peak sales of $4 billion.
The analyst said the... More
Horizon Therapeutics seen worth up to $140/share in takeover
November 30, 2022 8:12 AM ESTSeveral Wall Street analysts put pencil to paper after Horizon Therapeutics (NASDAQ: HZNP) said Tuesday evening that it was in "highly preliminary" takeover talks with Amgen Inc. (NYSE: AMGN), Janssen Global Services, LLC (NYSE: JNJ), and Sanofi (NYSE: SNY). A deal price as high as $140 per share was the high watermark discussed by at least two analysts.
Cowen analyst Ken Cacciatore said that given their belief that Tepezza's previous pause was... More
